X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.prnewswire.com/news-releases/cti-biopharma-presents-new-anemia-benefit-data-from-pacritinib-program-at-the-2022-american-society-of-hematology-ash-annual-meeting-and-exposition-301698750.html
https://www.prnewswire.com/news-releases/cti-biopharma-announces-presentation-of-new-anemia-benefit-data-from-pacritinib-program-at-the-society-of-hematologic-oncology-soho-tenth-annual-meeting-301630200.html
https://www.prnewswire.com/news-releases/cti-biopharma-presents-pivotal-data-from-pacritinib-program-at-the-european-hematology-association-eha-2022-congress-301565554.html
https://www.prnewswire.com/news-releases/nccn-guidelines-recommend-vonjo-pacritinib-for-the-treatment-of-myeloproliferative-neoplasms-301525508.html
https://www.prnewswire.com/news-releases/cti-biopharma-announces-fda-accelerated-approval-of-vonjo-pacritinib-for-the-treatment-of-adult-patients-with-myelofibrosis-and-thrombocytopenia-301492159.html
https://www.prnewswire.com/news-releases/cti-biopharma-presents-data-from-pacritinib-program-at-the-63rd-american-society-of-hematology-meeting-301442835.html
https://www.contractpharma.com/contents/view_breaking-news/2021-10-04/cti-biopharmas-pre-vent-trial-misses-endpoint-in-severe-covid/?widget=listSection
https://www.clinicaltrialsarena.com/news/cti-biopharma-pacritinib-study/
https://www.contractpharma.com/contents/view_breaking-news/2021-10-04/cti-biopharmas-pre-vent-trial-misses-endpoint-in-severe-covid/?widget=listSection
https://www.prnewswire.com/news-releases/cti-biopharma-announces-presentation-of-data-supporting-pacritinibs-potential-benefit-in-preventing-acute-gvhd-at-the-62nd-american-society-of-hematology-meeting-301186889.html
https://www.prnewswire.com/news-releases/cti-biopharma-initiates-rolling-submission-of-new-drug-application-nda-for-pacritinib-in-myelofibrosis-patients-with-severe-thrombocytopenia-301150876.html
https://www.prnewswire.com/news-releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19-301047305.html
https://www.prnewswire.com/news-releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19-301047305.html
https://www.prnewswire.com/news-releases/cti-biopharma-establishes-accelerated-approval-pathway-for-pacritinib-in-treating-myelofibrosis-patients-with-severe-thrombocytopenia-300997421.html
https://www.biospace.com/article/releases/cti-biopharma-begins-patient-enrollment-in-pacifica-pivotal-phase-3-trial-of-pacritinib-in-myelofibrosis-patients-with-severe-thrombocytopenia/?s=95
https://www.fiercebiotech.com/biotech/facing-rejection-cti-pulls-european-filing-for-pacritinib
https://www.ema.europa.eu/documents/agenda/agenda-chmp-agenda-28-31-january-2019_en.pdf
https://www.prnewswire.com/news-releases/cti-biopharma-provides-program-update-following-regulatory-feedback-from-the-us-fda-on-pacritinib-development-300768390.html
https://www.prnewswire.com/news-releases/cti-biopharma-announces-pacritinib-program-update-following-type-b-meeting-with-us-fda-300682676.html
Market Place
Share 
